Whitehawk CEO granted 193,957 options, 193,957 RSUs

Whitehawk Therapeutics granted its CEO a large stock option and RSU package with four-year service-based vesting.

Rhea-AI Filing Summary

Whitehawk Therapeutics, Inc. (WHWK) reported equity awards to Chief Executive Officer David James Lennon on September 15, 2026. He received a stock option for 193,957 shares of Common Stock at an exercise price of $4.09 per share, expiring September 15, 2036, and 193,957 Restricted Stock Units, each RSU representing one share of Common Stock.

Both awards vest based on continued service: for the option, 25% vests on the one-year anniversary of the September 15, 2026 Vesting Commencement Date and 1/48 of the total vests monthly thereafter until fully vested after four years; for the RSUs, 25% vests on each of the first four anniversaries of that Vesting Commencement Date.

Insider Trade Summary

Grant/Award: 387,914 shares

Grant/Award 2 txns

Insider Lennon David James

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy) F1	193,957	$0.00	$0.00
Grant/Award	Restricted Stock Units F2, F3	193,957	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 193,957 contracts (Direct); Restricted Stock Units — 193,957 contracts (Direct)

Footnotes (3)

1. F1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.
2. F2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
3. F3. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest on each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean September 15, 2026.

Key Figures

Stock options granted: 193,957 options RSUs granted: 193,957 RSUs Option exercise price: $4.09 per share +4 more

7 metrics

Stock options granted 193,957 options Stock option award to CEO David James Lennon on September 15, 2026

RSUs granted 193,957 RSUs Restricted Stock Unit award to CEO David James Lennon on September 15, 2026

Option exercise price $4.09 per share Exercise price of stock option covering 193,957 shares of Common Stock

Option expiration date September 15, 2036 Expiration of stock option granted to CEO

Initial option vesting portion 25% Portion of option shares vesting on first anniversary of September 15, 2026 Vesting Commencement Date

Ongoing option vesting rate 1/48 of total shares per month Monthly vesting schedule after first anniversary until four-year anniversary

RSU annual vesting portion 25% per year RSUs vest 25% on each of four anniversaries of the September 15, 2026 Vesting Commencement Date

Key Terms

Restricted Stock Units, Vesting Commencement Date, Service Provider, 2021 Equity Incentive Plan, +1 more

5 terms

Restricted Stock Units financial

"The security title includes Restricted Stock Units representing rights to shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Vesting Commencement Date financial

"Vesting Commencement Date shall mean September 15, 2026 for both awards"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

Service Provider financial

"Vesting is subject to continuing to be a Service Provider under the plan"

2021 Equity Incentive Plan financial

"Service Provider is defined in the Issuer's 2021 Equity Incentive Plan"

Common Stock financial

"Each RSU represents a contingent right to receive one share of Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did WHWK grant to its CEO on September 15, 2026?

Whitehawk Therapeutics granted CEO David James Lennon a stock option for 193,957 shares of Common Stock at an exercise price of $4.09 per share and 193,957 Restricted Stock Units, each RSU representing one share of Common Stock.

How do the new stock options for WHWK’s CEO vest?

The stock option vests if he continues as a Service Provider: 25% of the shares vest on the one-year anniversary of the September 15, 2026 Vesting Commencement Date, and 1/48 of the total vests monthly thereafter until fully vested on the four-year anniversary.

What is the vesting schedule for the WHWK CEO’s RSU award?

The RSU award vests based on continued service: 25% of the shares vest on the one-year anniversary of the September 15, 2026 Vesting Commencement Date, and 25% vest on each of the next three anniversaries of that date.

What is the exercise price and expiration of the WHWK CEO stock option?

The stock option granted to the WHWK CEO has an exercise price of $4.09 per share and an expiration date of September 15, 2036, subject to earlier termination under the company’s 2021 Equity Incentive Plan terms if applicable.

Are the WHWK CEO’s new awards tied to a Rule 10b5-1 trading plan?

No. The filing shows the Rule 10b5-1 checkbox as not affirmed, indicating these reported grants were not disclosed as being made under a Rule 10b5-1 trading plan.

What does each RSU granted to WHWK’s CEO represent?

Each Restricted Stock Unit represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock, subject to the vesting conditions and continued service requirements described in the company’s 2021 Equity Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 07:08 PM Accepted by SEC EDGAR 09/15/2026 - 07:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lennon David James

(Last) (First) (Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN NEW JERSEY 07960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$4.09	09/15/2026		A		193,957		(1)	09/15/2036	Common Stock	193,957	$0	193,957	D
Restricted Stock Units	(2)	09/15/2026		A		193,957		(3)	(3)	Common Stock	193,957	$0	193,957	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.

3. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest on each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean September 15, 2026.

	/s/ Stephen Rodin, as Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)